Results for tag: "Vitrakvi"

Vitrakvi is a targeted therapy drug used to treat certain types of cancer. It is a type of oncology drug, which is a drug used to treat cancer. Vitrakvi is a type of drug known as a TRK inhibitor, which works by blocking the activity of a gene called TRK. This gene is involved in the growth and spread of certain types of cancer. Vitrakvi is used to treat tumors that have a specific genetic mutation, known as a NTRK gene fusion. It is approved for use in adults and children with solid tumors that have this mutation. The Vitrakvi market is a rapidly growing segment of the oncology drug market. It is a relatively new drug, having been approved by the FDA in 2018, and is the first and only TRK inhibitor approved for use in the United States. Vitrakvi is a highly effective drug, with a high response rate in patients with the NTRK gene fusion. The Vitrakvi market is dominated by the drug's manufacturer, Bayer AG. Other companies in the market include Novartis, Pfizer, and Merck. Show Less Read more